CoChat

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Open access
Bronte, Giuseppe, Silvestris, Nicola, Castiglia, Marta, Galvano, Antonio, Passiglia, Francesco, Sortino, Giovanni, Cicero, Giuseppe, Rolfo, Christian, Peeters, Marc, Bazan, Viviana, Fanale, Daniele, Giordano, Antonio, Russo, Antonio · 2015 · Oncotarget
Cited by 84

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

// Giuseppe Bronte 1,* , Nicola Silvestris 2,* , Marta Castiglia 1 , Antonio Galvano 1 , Francesco Passiglia 1 , Giovanni Sortino 1 , Giuseppe Cicero 1 , Christian Rolfo 3 , Marc Peeters 3 , Viviana Bazan 1 , Daniele Fanale 1 , Antonio Giordano 4,5 and Antonio Russo 1 1 Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Medical Oncology Unit,National Cancer Institute “Giovanni Paolo II”, Bari, Italy 3 Department of Oncology, University Hospital of Antwerp, Edegem, Belgium 4 Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA 5 Department of Medicine, Surgery & Neuroscience, University of Siena, Siena, Italy * These authors equally contributed to this work Correspondence to: Antonio Russo, email: // Keywords : RAS, colorectal cancer, epidermal growth factor receptor, cetuximab, panitumumab Received : May 18, 2015 Accepted : July 04, 2015 Published : July 22, 2015 Abstract Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti-EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4959

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 84

Metadata

Authors
Bronte, G., Silvestris, N., Castiglia, M., Galvano, A., Passiglia, F., Sortino, G., Cicero, G., Rolfo, C., Peeters, M., Bazan, V., Fanale, D., Giordano, A., & Russo, A.
Venue
Oncotarget
Published
2015-07-22
Volume
6
Issue
28
Pages
24780-24796
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2098352219
Cited by
84
References
35
FWCI
6.24
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.